Formycon Wins Endorsement For Second EU Lucentis Rival
CHMP Positive Opinion For Ranivisio Sets Up Approval For Ranibizumab Biosimilar
Formycon has seen its FYB201 ranibizumab biosimilar rival to Lucentis recommended for approval by the EMA’s CHMP, under the name Ranivisio. Teva has rights to market the product in Europe and is preparing for launch.
You may also be interested in...
A busy August brings patent expiries, biosimilar target action dates and the potential for a major change to biosimilar prescribing guidelines in Germany.
Polpharma Biologics has claimed the first biosimilar natalizumab filing in Europe, after the European Medicines Agency accepted the firm’s marketing authorization application for review.
Four orphan drugs and a new COVID-19 vaccine are among the latest products that the European Medicines Agency says should be approved.